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Abstract
IMPORTANCE Reported increases in attention-deficit/hyperactivity disorder (ADHD) diagnoses are
accompanied by growing debate about the underlying factors. Although overdiagnosis is often
suggested, no comprehensive evaluation of evidence for or against overdiagnosis has ever been
undertaken and is urgently needed to enable evidence-based, patient-centered diagnosis and
treatment of ADHD in contemporary health services.
OBJECTIVE To systematically identify, appraise, and synthesize the evidence on overdiagnosis of
ADHD in children and adolescents using a published 5-question framework for detecting
overdiagnosis in noncancer conditions.
EVIDENCE REVIEW This systematic scoping review adhered to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses (PRISMA) Extension for Scoping Reviews and Joanna Briggs
Methodology, including the PRISMA-ScR Checklist. MEDLINE, Embase, PsychINFO, and the Cochrane
Library databases were searched for studies published in English between January 1, 1979, and
August 21, 2020. Studies of children and adolescents (aged 18 years) with ADHD that focused on
overdiagnosis plus studies that could be mapped to 1 or more framework question were included.
Two researchers independently reviewed all abstracts and full-text articles, and all included studies
were assessed for quality.
FINDINGS Of the 12 267 potentially relevant studies retrieved, 334 (2.7%) were included. Of the 334
studies, 61 (18.3%) were secondary and 273 (81.7%) were primary research articles. Substantial
evidence of a reservoir of ADHD was found in 104 studies, providing a potential for diagnoses to
increase (question 1). Evidence that actual ADHD diagnosis had increased was found in 45 studies
(question 2). Twenty-five studies showed that these additional cases may be on the milder end of the
ADHD spectrum (question 3), and 83 studies showed that pharmacological treatment of ADHD was
increasing (question 4). A total of 151 studies reported on outcomes of diagnosis and pharmacological
treatment (question 5). However, only 5 studies evaluated the critical issue of benefits and harms
among the additional, milder cases. These studies supported a hypothesis of diminishing returns in
which the harms may outweigh the benefits for youths with milder symptoms.
CONCLUSIONS AND RELEVANCE This review found evidence of ADHD overdiagnosis and
overtreatment in children and adolescents. Evidence gaps remain and future research is needed, in
particular research on the long-term benefits and harms of diagnosing and treating ADHD in youths
with milder symptoms; therefore, practitioners should be mindful of these knowledge gaps,
especially when identifying these individuals and to ensure safe and equitable practice and policy.




overdiagnosed in children and
adolescents?
Findings In this systematic scoping
review of 334 published studies in
children and adolescents, convincing
evidence was found that ADHD is
overdiagnosed in children and
adolescents. For individuals with milder
symptoms in particular, the harms
associated with an ADHD diagnosis may
often outweigh the benefits.
Meaning This finding suggests that
high-quality studies on the long-term
benefits and harms of diagnosing and
treating ADHD for youths with milder or
borderline symptoms are needed to
inform safe and equitable practice
and policy.
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Introduction
Public debate over the appropriateness of attention-deficit/hyperactivity disorder (ADHD) diagnosis
has grown along with diagnosis rates.1-6 Disagreement continues about how much of the increased
diagnoses can be attributed to true increases in frequency, improved detection, or diagnostic
inflation because of misdiagnosis and/or overdiagnosis.7-12 The concept of overdiagnosis is well
established in cancer,13,14 but it also occurs in noncancer conditions.15-17 Methods to investigate
overdiagnosis in noncancer conditions were published recently18 but have not been applied to
ADHD yet.
Overdiagnosis of ADHD could happen because of diagnostic inflation10,19 by widening the
definition to include ambiguous or mild symptoms, by explicitly changing the diagnostic
definition,10,20 or by implicitly medicalizing behavioral patterns that previously would not have been
considered abnormal1,21 (eg, those behaviors that are typical of children who are relatively young for
their school year22). However, for increased detection to represent current overdiagnosis rather than
previous underdiagnosis of ADHD, we also need evidence that these additional cases do not derive
a net benefit from diagnosis (ie, these children’s overall health is not improved because the harms of
diagnosis and treatment outweigh the benefits23-25). Although the benefits of appropriate diagnosis
and treatment of ADHD may be well known,12 harms are less well appreciated. Physical and
psychosocial harms (and financial costs) may be experienced directly by the young patients and their
family, but economic and opportunity costs are experienced by the wider society.7
In this study, we systematically reviewed the literature to identify, appraise, and synthesize the
evidence on overdiagnosis of ADHD in children and adolescents. Moreover, we aimed to highlight
any existing evidence gaps. We used a 5-question framework for detecting overdiagnosis in
noncancer conditions.
Methods
Because of the broad research question, we conducted a systematic scoping review that adhered to
the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Extension for
Scoping Reviews26 and Joanna Briggs Methodology,27 including the provision of a PRISMA-ScR
Checklist. A summary of the methods is given here, and the details are published elsewhere.28
Overdiagnosis is defined here as occurring when a person is clinically diagnosed with a
condition, but the net effect of the diagnosis is unfavorable.18,23,29 Misdiagnosis (when a child is
incorrectly labeled with an ADHD diagnosis instead of an alternative condition10,23) and false-positive
diagnosis (when a subsequent clinical encounter reveals a wrong initial diagnosis23) are not the focus
of this article.
The conceptual basis for this review was a previously published framework for identifying
characteristics that are consistent with overdiagnosis and subsequent overtreatment in noncancer
conditions.18 All included data were mapped to these 5 questions: (1) Is there potential for increased
diagnosis? (2) Has diagnosis actually increased? (3) Are additional cases subclinical or low risk? (4)
Have some additional cases been treated? (5) Might harms outweigh benefits of diagnosis (5a) and
treatment (5b) (Figure 1)?
Peer-reviewed primary and secondary studies in children and adolescents that were published
in English between January 1, 1979, and August 21, 2020, were eligible for inclusion. Studies with
mixed-age populations were included if it was possible to extract data from them separately or if
most participants were aged 18 years or younger. Given the overwhelming amount of evidence on
pharmacological ADHD treatment outcomes, we included systematic reviews and cohort studies
only for question 5b. Studies needed to have a clear emphasis on ADHD.
Searches were performed on August 21, 2020, in MEDLINE, Embase, PsychINFO, and the
Cochrane Library (eAppendix 1 in Supplement 1). These database searches were supplemented by
backward citation searches of all included articles and forward citation searches on key research.
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After the removal of duplicates and a pilot phase, 2 of us (L.K. and R.S.) independently screened
abstracts using the web-based text mining tool Abstrackr (Brown University).30,31 Subsequently, the
full texts of all potential articles were independently reviewed by 1 of us (L.K.) and another
researcher. Any discrepancies were resolved through discussion.
Data Extraction and Quality Assessment
Data were extracted into a standardized template, which was developed through an iterative process
(eAppendix 2 in Supplement 1). Data from qualitative studies were mapped using NVivo, version 12
Plus (QSR International). Uncertainties were resolved by team discussion. A quality assessment of
included studies was conducted by one of us (L.K.) using critical appraisal checklists developed by the
Joanna Briggs Institute.32
Data Synthesis and Analysis
Data were considered in the context of the 5 questions and then stratified into themes and
subthemes for analysis. Each study could contribute data to more than 1 question.
To investigate whether a reservoir of potentially diagnosable ADHD existed (question 1), we
looked for prevalence variations and other indicators, such as evidence of a spectrum of symptoms.
For example, the lack of biological explanations for large prevalence variations among populations or
among diagnostic standards would indicate a reservoir of potentially diagnosable disease. To analyze
the data on ADHD diagnosis and treatment patterns (questions 2 and 4), we included any studies
that provided time-trend data on clinical diagnosis or medication rates.
The question of whether additional diagnoses were predominantly mild cases (question 3) was
central to ascertaining whether extra detection represented a net benefit or harm. However, severity
of ADHD was not consistently defined or assessed, relying heavily on subjective interpretations.25
We grouped the evidence for this question into 2 categories: studies that reported ADHD severity
and studies that reported degree of impairment as a proxy.
We divided the evidence on benefits and harms (question 5) into outcomes of the diagnosis and
outcomes of any subsequent treatment, with a focus on the ratio of benefits to harms specifically for
youths with milder ADHD-related behaviors.18 In addition, we considered the evidence on benefits
and harms across the wider ADHD spectrum.


























Higher diagnostic threshold marked by the tidelineA Lower diagnostic threshold marked by the tidelineB
The model of an iceberg illustrates how the framework relates to subsets of the
population who may be diagnosed with ADHD. Question 1 concerns youths who may be
diagnosable with ADHD, question 2 concerns youths who are diagnosed with ADHD
according to newer criteria or those who were already diagnosed with ADHD using older
thresholds, and questions 3 to 5 concern youths who are newly diagnosed vs those who
are already diagnosed (adapted from Bell et al18).
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Results
Of the 12 267 records retrieved, 334 studies (2.7%) were included. eAppendix 3 in Supplement 1
outlines the selection process in a PRISMA flow diagram.26
Of the 334 included studies, 61 (18.3%) were secondary and 273 (81.7%) were primary research
articles. Most studies were published within the past 10 years (n = 217 [65.0%]) and were most
commonly from North America (n = 128 [38.3%]), Europe (n = 93 [27.8%]), or Oceania/Asia (n = 35
[10.5%]) (Table 1; eAppendix 4 in Supplement 1 and Supplement 2).
The quality of included studies varied; approximately one-third of the studies were classified as
having low (n = 129), moderate (n = 102), or high (n = 103) risk of bias. Studies that provided
evidence for question 5 were more likely to be at high risk of bias (n = 69 [45.7%]) (Figure 2 and
eAppendix 5 in Supplement 1).
Table 2 maps the evidence against the framework.1-3,5,6,10,11,20-22,33-356 A summary of the
findings is described here. The full results are provided in eAppendix 6 in Supplement 1.
Large Reservoir of Potentially Diagnosable ADHD
A total of 104 studies were included to answer question 1. Large variations in ADHD diagnosis were
found between subpopulations in 48 studies. Twenty-five studies provided evidence of variation
between the sexes, showing lower diagnosis of ADHD in girls than in boys. Although biological
reasons may exist,38,45 equally symptomatic girls were less likely to be diagnosed than boys in 2
studies.54,55 Eight studies showed decreasing ratios over time, which were indicative of a reservoir of
diagnosable ADHD in girls.5,6,34,37,40,41,44,47
Of the 12 included studies that focused on relative age, 11 studies showed that the youngest
children in class were more likely to be diagnosed with ADHD than the oldest children.22,68-77 One
study did not confirm this finding.78 It was conducted in a low-prevalence setting in which only









North America 128 (38.3)
Rest of Europe 35 (10.5)
Scandinavia 33 (9.9)
United Kingdom/Ireland 25 (7.5)
Asia 18 (5.4)
Australia/New Zealand 17 (5.1)
Middle East 10 (3.0)




Diagnostic test accuracy 9 (2.7)
Prevalence 142 (42.5)
Qualitative 12 (3.6)
Randomized clinical trial 14 (4.2)
Systematic review 44 (13.9)
Other review 17 (5.1)
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specialists diagnosed ADHD, suggesting that variation (and a potential reservoir) is much smaller
where stricter adherence to diagnostic criteria may occur.
Youths from various migrant backgrounds were traditionally less likely to be diagnosed with
ADHD in 15 studies.6,35-37,41,42,45,48,49,53,56,62,63,65,66 However, there is evidence that diagnosis rates
increased rapidly (especially in young Black youths, often overtaking the rates in White
youths).6,37,39,41,51,52,56,66,67 Twenty-one studies5,6,35,36,39,41,43,45,46,49,53-64 on diagnostic variation by
socioeconomic or health insurance status and 8 studies6,33,35,36,39,46,56,59 on regional variation all
demonstrated substantial differences.
Eighteen of 20 studies that compared diagnostic prevalence between 2 or more diagnostic
criteria described a concurrent increase in potential cases with the broadening of criteria.10,20,52,79-93
Twenty-two studies reported a spectrum of ADHD-related behaviors showing that problems existed
on a continuum, with ADHD on the extreme end in 7 studies119,124-129 and subthreshold behaviors
on the other end displayed by a considerable proportion of young people in 8
studies,108-110,114,115,121-123 indicating a large reservoir of potentially diagnosable ADHD. This
continuum was also described by a higher risk of adverse outcomes with increasing ADHD symptoms
from subthreshold symptom levels to severe behaviors in 13 studies.108-120
Evidence of expanding reservoirs attributed to the medicalization of behavior was found in 3
studies.57,96,97 Four of 5 phenotype change studies reported stable or declining ADHD symptoms in
the population, making it unlikely that the expansion was associated with an actual increase in ADHD
symptoms over time.1,21,98,99
Sixteen studies that investigated diagnostic inaccuracies as a reason for variation reported
potential underdiagnosis because of false-negative diagnosis1,21,38,104,105 and potential overdiagnosis
because of false-positive diagnosis,54,93,100,106,107 often occurring simultaneously.11,64,65,101-103
Consistent Increases in ADHD Diagnosis Between 1989 and 2017
Of the 45 studies included to answer question 2, 30 studies estimated change in diagnostic
prevalence of ADHD over time, with 27 documenting increased
trends3,5,21,34,39,41,44,47,50,61,66,74,130-144 and 3 observing a plateau in the early 2000s.33,60,145 Similar
evidence came from studies that measured trends in annual diagnostic
incidence2,3,40,43,44,60,140,142,146-149 or lifetime diagnostic prevalence,1,2,5,6,21,36,37,40,53,56,58,150 with
nearly all of these studies (96.0%) confirming continuously increasing ADHD diagnoses.
Figure 2. Risk of Bias (ROB) Assessment














Percentage of studies per ROB level
Total
20
Low ROB Moderate ROB High ROB
The full results from the critical appraisals are found in
eAppendix 5 in Supplement 1.
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Many Additional Cases On the Milder End of the ADHD Spectrum
Twenty-five studies were included to answer question 3. Five studies reported that only a small
proportion of all diagnosed youths displayed severe ADHD behaviors.5,36,132,138,152
Eleven studies used changes in impairment as a proxy for severity. Eight of these studies
confirmed that impairment levels, adverse outcomes, and benefits of medication substantially









Question 1. Is there potential for increased diagnosis (n = 104 studies)
Prevalence
variations (68)
By subpopulation (48) Sex (25) Lower diagnosis in girls than boys (23)5,6,33-53
Symptomatic girls less likely to be diagnosed (2)54,55
SES or insurance status (21) Higher diagnosis in lower SES (13)5,6,35,36,39,43,45,46,49,53,56-58
Higher diagnosis in higher SES (2)59,60
Higher diagnosis in public vs private health insurance (5)5,41,53,58,61
Lower diagnosis in no vs any health insurance (7)5,53,54,58,62-64
No association of insurance status with diagnosis in hypothetical scenario (1)55
Race/ethnicity (21) Lower diagnosis in Black and Hispanic vs White youths (14)6,35-37,41,42,48,49,53,56,62,63,65,66
Lower diagnosis in White vs Black youths (4)39,51,52,67
Lower diagnosis in non-English-speaking and migrant youths (3)35,36,45
No association of race/ethnicity with diagnosis in hypothetical scenario (1)55
Relative age (12) Youngest children in class more likely to be diagnosed (11)22,68-77
No difference in diagnosis probability by relative age (1)78
Location/region (8) Large variations in diagnosis by region (8)6,33,35,36,39,46,56,59
Other (1) Higher diagnosis and reported symptoms in larger classes (1)42
By diagnosis (20) Diagnostic criteria (20) Broadening of criteria associated with increases in potential cases in comparisons between
any DSM version and/or ICD-10 (18)10,20,52,79-93
Broadening of age of onset associated with minimal increases in potential cases (2)94,95
Reservoir (44)
attributed to
Medicalization (3) Behavioral problems (3) Society’s decreasing tolerance for different behavior associated with increased range of
behavior diagnosed as abnormal (2)57,96
Mental health professionals from China and Indonesia rating same attention difficulties
higher than mental health professionals from US and Japan (1)97
Phenotype changes (5) Trends over time (5) No increase in clinically significant symptoms (4)1,21,98,99
Increase in youths with clinically significant symptoms (1)100
Increase in subthreshold symptoms (1)1
Diagnostic inaccuracy (16)
associated with
Over- and underdiagnosis (16) Potential over- and underdiagnosis occurring (6)11,64,65,101-103
Potential underdiagnosis attributed to false-negatives (5)1,21,38,104,105
Potential overdiagnosis attributed to false-positives (5)54,93,100,106,107
Spectrum of disorder (22)
indicated by subtheme
Implications of extent of
symptoms over time (13)
Continuous association between increasing symptoms and increased risk of various later
adverse outcomes (13)108-120
Subthreshold prevalence (8) Many youths with subthreshold symptoms (6)108-110,114,115,121
Percentage of youths with symptoms decreases with age (2)122,123
Verification of dimensional
structure (7)
Inattention, hyperactivity, and impulsivity problems exist on a spectrum with ADHD at the
end (7)119,124-129
Question 2. Has diagnosis actually increased? (n = 45 studies)
Diagnosis (45) Trend over time (45)
indicated by subtheme
Change in prevalence (30) Increasing trend (27)3,5,21,34,39,41,44,47,50,61,66,74,130-144 until early 2000s (3)33,60,145
Change in incidence (12) Increasing trend (11)2,3,40,43,44,140,142,146-149 until 2007 (1)60
Change in lifetime prevalence (12) Increasing trend (11)1,2,5,6,21,36,37,40,53,56,150
Stagnant in adolescents and increasing in children (1)58






Change in adverse outcomes
over time (2)
Decreasing problems with increasing ADHD group (1)100
Reduction in hospital visits in medicated children decreasing with increasing group of youths
with ADHD (1)150,b
Difference in adverse outcomes
by diagnostic criteria (9)
Broadening of diagnostic criteria and increasing of ADHD group associated with less
impairment (5)79,85,86,88,93
Reduction in symptoms and impairments in medicated children decreasing with broadening
of ADHD criteria (1)151,b
Sample size too small to detect differences (4)84,87,94
Symptom severity (6)
indicated by subtheme
Trend over time (3) Severity proportions stable (1)132
Larger increase in moderate/severe cases (2)5,138
Severity proportions (2) Proportion of youths with severe ADHD being low (2)36,152
Diagnostic criteria (1) No difference in severity between late and early-onset cases (1)92
Levelofsymptoms(8) Clinically significant symp-
tom prevalence (8) by
Change over time (8) PrevalenceestimatesofsymptomaticADHDremainingsteadyorslightlydecreasing(6)1,21,90,91,98,99
Relative age effect increasing in later birth cohorts (2)70,75
(continued)
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decreased with the expansion of the group of diagnosed youths.79,85,86,88,93,100,150,151 Six studies that
confirmed stable or declining ADHD behaviors in youths over several decades supported this
finding.1,21,90,91,98,99 Correspondingly, 2 studies70,75 on the relative age effect on ADHD diagnosis
reported that the proportion of youngest children in class who received a diagnosis compared with
older children had increased in more recent birth cohorts. In contrast, 3 studies5,132,138 that reported
time trends of parent- or clinician-perceived severity of the disorder showed larger relative increases
in more severe cases (which could be associated with a growing tendency to report the same
behaviors as more severe).
Substantial Increases in Pharmacological Treatment for ADHD
Between 1971 and 2018
Of the 83 studies included to answer question 4, 64 showed an increasing percentage of youths
being pharmacologically treated for ADHD. Three studies194,195,213 identified a plateau or decrease in
this trend for preschool-aged children, with 2 studies134,163 indicating a general declining trend in
youths in Germany who received treatment. Annual incident treatment rates were reported to be
increasing in 5 studies142,166,175,196,197 and to be stable or without a clear trend in 4 studies,172,198-200
whereas 10 of 11 studies50,201-209 reported increasing trends in medication dispensing or sales.
Benefits May Be Outweighed by Harms in Youth With Milder ADHD Symptoms
Diagnosis | A total of 31 studies reported the consequences of diagnosis (question 5a). We focused
on the benefits and harms for milder cases. Only 2 studies64,233 provided information on this group
and both reported harms and found that the diagnostic label could have adverse social,
psychological, and academic effects when compared with undiagnosed youths with similar
behaviors.
Regarding the general benefits of a diagnosis (across the full spectrum of ADHD cases), 2 main
themes emerged. First, in 14 studies, an ADHD diagnosis was shown to create a sense of









Question 4. Have some additional cases been treated? (n = 83 studies)
Medication (83) Trend over time (83)
indicated by subtheme
Prevalent treatment rate (58) Increasing trend (55)2,5,34,39,40,50,58,74,133,136,141-143,150,153-193
Decreases in those younger than 6 years and increases in those older than 6 years (2)194,195
Mostly decreasing trend (2)134,163
Incident treatment rate (9) Increasing trend (5)142,166,175,196,197
Stable or variable rate (4)172,198-200
Medication use (11) Increasing trend (10)50,201-209 until 2010 (1)210
Consultations in which ADHD
medication is prescribed (10)
Increasing trend (9)41,47,132,135,139,144,145,211,212
Increasing trend until 2004 in those younger than 6 years (1)213
Question 5a. Might harms outweigh benefits of diagnosis? (n = 31 studies)
Potential benefits
of diagnosis (15)
Empowered (14) through Explanation for problems (11) Increased legitimacy and validation (5)57,214-217
Increased understanding, sympathy, and reassurance (8)215-222
Decreased guilt, blame, failure, and anger (6)57,214,215,219,222,223
Increased control (6) Decreased uncertainty; feeling of identity and belonging (3)215,218,223
Increased self-esteem and confidence (3)215,218,220
Expectation of solution (4)214,215,218,222





Excuse for problems (15) Decreased responsibility for behaviors and problems (6)96,214,216,220,224,225
Increased deflection from underlying problems (3)57,214,215
No meaningful benefit from diagnosis or no change (10)96,103,216,218,220,222,226-229
Loss of control (15) Associated with control and manipulation by others (4)96,214,220,223
Increased passiveness and hopelessness (3)215,216,222
Self-fulfilling prophecy: perceived inability to change or achieve (by self or others)
associated with exclusion and fewer opportunities (9)64,215,217,230-235,b
Stigmatization (14)
through
Permanent label and identity (14) Enhanced prejudice, stereotypes, and judgment (14)215-218,220,222,225,230,232,236-240
Increased feelings of isolation, exclusion, and shame (3)216,220,225
(continued)
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Academic (19) Cognitive and motor
functioning (4)
Improvements in commission errors only; all others unchanged (1)241
Favorable outcomes in several aspects of cognition (1)242 and motor skills (1)243
No change after washout period (1)228
Academic performance (15) Worse educational outcomes in treated vs rest of the population (1)244
No treatment effect (3)245-247
Some small favorable outcomes in treated vs untreated youths (6)248-253
Substantial improvement in treated vs untreated or less treated youths (2)254,255
Decrease in academic outcomes after increased medication treatment (1)256
Potential harmful outcome, especially in youths with less severe symptoms (1)64,b
Medication treatment only beneficial for youths with more severe symptoms (1)233,b
Accidents (12) ED use and hospital admissions (5) Fewer hospital contacts in treated vs untreated youths, but outcomes smaller in later, larger
diagnosed and treated cohorts (1)150,b
No change in hospital contacts in treated vs untreated periods and youths (2)257,258
Fewer hospital contacts during treated vs untreated periods (2)257,259
Worse health outcomes in treated vs rest of the population (1)244
Injuries and poisoning (8) Lower risk of injuries in treated vs untreated periods (3)259-261 and youths (2)262,263
No change in injuries (1)264 or MVAs (1)265 during treated vs untreated periods
Increase in unintentional poisonings with ADHD medication (1)266
Cardiovascular (8) Blood pressure and heart rate (2) No association of treatment with blood pressure (2)267,268 but with heart rate (1)268
Safety (6) No association of treatment with severe cardiovascular events (3)269-271
Increased risk of arrhythmia (1)272 or any serious cardiac event (1)273
Not enough statistical power to detect small differences (3)269,270,274
Efficacy (30) Symptom reduction (30) Substantial short-term symptom reduction for many (24)196,241,247,275-295
No symptom improvement after 48-hour washout period (1)296
No long-term difference in treated vs untreated youths (3)245,297,298
Individuals with more severe symptoms at baseline showed greatest treatment response in
the long term (5 years) (1)299,b
Physical (14) Activity (2) Lower levels of physical activity in treated vs untreated periods (1)300 and youths (1)301
Height (12) and weight (5) Growth delay (2)302,303 and decreased growth (6)297,304-308 or weight (3)304,305,308
No change observed and substantial heterogeneity (5)267,301,303,309,310
Psychological (20) Other (2) Increased risk of psychosis (1)311 and tics (1)312
Substance abuse (12) No association of treatment with later substance abuse (4),313-316 reduced risk (5),317-321
and increased risk of stimulant abuse (1)322
Prescription stimulant misuse or diversion in youths with or without ADHD (2)323,324
Suicidal behavior (6) No association of treatment with risk of suicidal behavior (2),325,326 reduced risk (3),327-329
and increased risk (1)330
Social and emotional (11) Emotional (3) Increased risk of irritability with amphetamine treatment (1)331
Mixed outcomes for various emotional behaviors with stimulant treatment (1)332
Decrease in happiness after increased medication treatment (1)256
Criminal behavior (3) Reduced risk of conviction and incarceration in treated vs untreated periods (1)333
No change in risk of receiving driving citation for treated vs untreated periods (1)265
Reduced risk of being charged with a crime in treated vs untreated youths, but effects were
smaller in later, larger diagnosed and treated cohorts (1)150,b
Social impairment (2) Little change in social impairment in treated vs untreated period (1)246
Potentially relevant improvements in some domains in treatment vs placebo group (1)334
Quality of life (4) Small short-term improvements in quality of life (3)334-336; no impact (1)337
Tolerability (29) Adverse events (25) Low occurrence of mild AEs (2)196,277
Relatively common mild or moderate AEs (16)276,278,280,281,286,289,291,292,294,295,299,338-342
Young children more vulnerable to AEs (2)295,343
Reporting of AEs unsatisfactory (6)282,291,294,344-346
Serious AEs rare but difficult to determine from reported data (5)287,338,340,345,346
Discontinuation (6) Moderate to high discontinuation rates (20%-44%) (4)290,341,347,348
Discontinuation similar to placebo group or low-quality evidence (2)275,285
Various (8) Mixed (8) 50% of various outcomes reported some benefits of treatment (1)349
Reduced risk of various outcomes (2)350,351
Lack of methodologically sound research on which to base decisions (1)352
Longer treatment duration indicated better outcomes for various domains (1)353
No long-term treatment effect for various functioning outcomes (3)354-356
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AE, adverse event; DSM,
Diagnostic and Statistical Manual of Mental Disorders; ED, emergency department;
ICD-10, International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision; MVA, motor vehicle accident; SES, socioeconomic status.
a Full main results are presented in eAppendix 6 in Supplement 1.
b Items refer specifically to the benefits and harms for young people with less severe
ADHD behaviors.
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empowerment for those involved. It provided a biomedical explanation for experienced problems,
supporting a sense of legitimacy57,214-217 accompanied by understanding and sympathy215-222 as well
as decreased guilt, blame, and anger.57,214,215,219,222,223 Subsequently, this explanation could increase
perceived control, with expectations of solutions,214,215,218,222 enhanced confidence,215,218,220 and
a sense of belonging.215,218,223 Second, enablement was often experienced57,96,214-217,219,220,222,223
and was characterized by increased support accompanying a diagnosis of ADHD and by an enhanced
ability to seek and accept help.215,216,222,223
Two themes related to potential harms also emerged. First, in 22 studies, a biomedical view of
difficulties was shown to be associated with disempowerment. By providing an excuse for problems,
a decrease in responsibility by all involved can occur,96,214,216,220,224,225 often followed by inaction
and stagnation.96,103,216,218,220,222,226-229 This view can also deflect from other underlying individual,
social, or systemic problems,57,214,215 which can prompt a self-fulfilling prophecy, wherein the
perceived inability to change reduces opportunities64,215,217,230-235 as well as promotes hopelessness
and passiveness.215,216,222 This loss of control may be especially high when the diagnosis is used as a
step toward coercing young people into correcting arguably problematic behaviors.96,214,220,223
Second, 14 studies reported on stigmatization. The diagnosis can create an identity that enhances
prejudice and judgment,215-218,220,222,225,230,232,236-240 which are associated with even greater
feelings of isolation, exclusion, and shame.216,220,225
Treatment | A total of 120 studies reported on the consequences of pharmacological treatment.
Forty studies reported on the direct outcomes of pharmacological treatment of ADHD, including 2
studies151,299 on treatment efficacy stratified by severity of ADHD behaviors. These studies
confirmed substantially greater treatment response in youths with more severe symptoms at
baseline and diminished benefits in milder cases. None of the 29 studies that reported on direct
harms of treatment differentiated between case
severity.196,275-278,280-282,285-287,289-292,294,295,299,338-348
Of the 85 studies on indirect outcomes of treatment, 3 studies reported on youths with less
severe ADHD. Two of these articles64,233 suggested that treatment was only beneficial to academic
outcomes in youths with severe symptoms, with 1 study64 reporting a potentially harmful outcome in
milder cases. Another study150 found that the benefits of medication in reducing hospital contacts
and criminal behavior were smaller in later birth cohorts for whom treatment prevalence was higher
(thus likely expanding treatment to milder cases).
Twenty-four studies that reported the direct outcomes of medication across the spectrum of
symptoms supported substantial short-term symptom reduction.196,241,247,275-295 However, only 3
studies245,297,298 reported long-term follow-up beyond active treatment, finding no difference in
symptoms between youths who were treated and those who were untreated in later life, and
another study296 found no difference in symptoms after a 48-hour washout period. In terms of
harms, active treatment was commonly associated with mild and moderate adverse
events276,278,280,281,286,289,291,292,294,295,299,338-342 and high discontinuation
rates.275,285,290,341,347,348 Ten studies mentioned unsatisfactory reporting of
harms.282,287,291,294,338,340,344-346
Indirect treatment effects (across the spectrum of ADHD symptoms) were documented for
diverse outcomes, including academic,64,233,244-256 cardiovascular,267-274 physical,267,297,300-310
psychological,311-316,327-329 social and emotional,150,246,256,265,331,333-337 and accidents.150,244,257-266
We found evidence of benefits for academic outcomes,241-243,248-255 injuries,259-263 hospital
admissions,150,257,259 criminal behavior,150,333 and quality of life.334-336 In addition, harmful outcomes
were evident for heart rate and cardiovascular events,268-270,272-274 growth297,302-308 and
weight,304,305,308 risk for psychosis and tics,311,312 and stimulant misuse or poisoning.266,322-324
Treatment was associated with reduced physical activity in 2 studies. For suicidal behavior as well as
emotional and social impairment, we could not find any favorable or unfavorable patterns.
JAMA Network Open | Pediatrics Overdiagnosis of ADHD in Children and Adolescents
JAMA Network Open. 2021;4(4):e215335. doi:10.1001/jamanetworkopen.2021.5335 (Reprinted) April 12, 2021 9/29
Downloaded From: https://jamanetwork.com/ by a Bond University User  on 04/18/2021
The findings suggest that relatively large symptom reductions through medication translate to
modest decreases in functional impairment at best while carrying risks. This ratio is likely worse for
youth with milder ADHD in which large symptom reductions are impossible.
Discussion
To our knowledge, this study is the first systematic scoping review on overdiagnosis of ADHD in
youths. We found evidence of overdiagnosis and overtreatment of ADHD. We confirmed a large
reservoir of diagnosable ADHD, consistently increasing rates of ADHD diagnosis and treatment, and
a large proportion of newly detected cases with milder symptoms (in which harms may outweigh
smaller benefits of diagnosis and treatment). Furthermore, we found few studies that assessed
symptom severity among extra cases diagnosed through expanded disease definitions as well as the
balance of benefits and harms for these individuals, representing a critical evidence gap.
Implications of Findings
Our findings have implications for these individuals, who may be harmed by overdiagnosis and the
adverse effects of medication during childhood, adolescence, and even adulthood. These findings
are also relevant to the growing number of adults being newly diagnosed with ADHD4 and may be
applicable to other conditions, such as autism.358
Several important research questions emerged during this review. Larger studies need to be
conducted to confirm whether the additional ADHD cases now being diagnosed have milder
symptoms. Future research is also required to evaluate whether diagnosing and treating milder
ADHD cases may carry net harm. To reduce health and educational inequities, resources must be
shifted from the overdiagnosis and overtreatment of ADHD to the needs of youths with more severe
symptoms and who are more likely to benefit, including those currently underdiagnosed. Our
research focused on overdiagnosis, and we did not address the misdiagnosis and underdiagnosis of
ADHD. Although they are outside of the scope of this study, misdiagnosis and underdiagnosis are
important complementary issues in a broader discussion of the principles of “right” care359 and
equitable use of health care resources.360
We recommend that practitioners, parents, and teachers carefully weigh the potential benefits
and harms that can accompany ADHD diagnosis and treatment, especially when identifying youths
(or adults) with milder symptoms. For this group, the benefits of diagnosis and treatment may be
considerably reduced or outweighed by harms.
An option to improve the balance of benefit to harm in practice may be to follow a stepped-
diagnosis approach, as described by Batstra et al9 and Thomas et al.25 This approach incorporates the
valid need for efficient diagnosis and treatment for severe cases as well as a watch-and-wait
approach for borderline cases. It echoes management by active surveillance of low-risk prostate,
breast, and thyroid cancers, in which overdiagnosis occurs frequently,361 and it ensures that
resources are allocated where they are needed most and will be most valuable.359
Strengths and Limitations
This study has several strengths. The 5-question framework enabled us to undertake a systematic
scoping review, in accordance with international standards,26 to synthesize a large, heterogeneous
set of studies. We undertook a critical appraisal of the included studies32 that allowed us to evaluate
the quality of the evidence collected globally over many decades. Previous analyses focused on
specific aspects of ADHD overdiagnosis, such as the existence of a relative age effect,72 differences
between diagnosis and phenotype trends,21 or outcomes of medication.294,346 Although they
contributed important evidence to the literature, these earlier studies were unable to draw overall
conclusions on overdiagnosis of ADHD, which we were able to do.
This study also has several limitations. First, despite the inclusion of studies from many
countries over a long period, these findings may not be applicable to all demographic groups. Given
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the scope of this study, we restricted the evidence for questions 4 and 5 to pharmacological
treatment of ADHD, which is the most common and controversial treatment. Second, this review is
limited by the availability and quality of evidence. Although our confidence in the outcomes for
questions 2 and 4 is high, many studies included for questions 1, 3, and 5 were at high risk of bias.
Third, parents or teachers were often the sole reporters of potentially subjective measures (eg,
symptom severity, quality of life, and consequences of diagnosis). This lack of self-reported data
means that it is unknown whether benefits and harms may have been reported differently by the
youths themselves.
Conclusions
In this systematic scoping review, we found convincing evidence of ADHD overdiagnosis and
overtreatment in children and adolescents. Despite an abundance of research in the field of ADHD,
gaps in evidence remain. In particular, high-quality studies on the long-term benefits and harms of
diagnosing and treating ADHD in young people with milder symptoms are needed to inform safe and
equitable practice and policy.
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